21st Austria weekly - Marinomed Vienna Insurance Group 21/11/2023 [pic1]Marinomed: Marinomed Biotech AG recorded stable revenues of € 7.2 million in the first three quarters 2023 Q1-Q3 2022: 7.1 million due to continued demand for Carragelose virus blockers. The increase personnel costs higher R&D expenses and lower research subsidies were reflected operating result -4.4 -3.8 million. period amounted -5.6 million compared -5.8 prior-year period. For platform took necessary steps create an all-year product portfolio a expansion therapeutic area immunology with allergy blocker eye drops. market launches are already preparation 2024. Procter & Gamble also secured rights Carragelose-based spray USA. has paved way further important partnerships candidates Budesolv Tacrosolv which based on Marinosolv
21st Austria weekly - Marinomed Vienna Airport Kapsch TrafficCom Andritz Valneva Addiko 17/08/2023 [pic1]Marinomed: Marinomed Biotech AG reported a rise of revenues for the first half 2023 +7% to € 5.2 million after 4.9 in H1 2022 driven by continued strong demand Carragelose products. The operating result period was -2.9 H1 2022: -2.5 million due increased R&D expenses and personnel costs. successful obtaining market authorization Mexico as well expansion portfolio with an eye drop product anti-allergic next season 2024. Supported excellent clinical data its two Marinosolv-based candidates Tacrosolv Budesolv company pushed business development activities aim enter new partnership end year. also entered long-term Solv4U dynamic Chinese